The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects
Abstract
UNLABELLED: The objectives of this study were to examine the effective dose range and the test-retest reliability of florbetapir F 18 using, first, visual assessment by independent raters masked to clinical information and, second, semiautomated quantitative measures of cortical target area to cerebellum standardized uptake value ratios (SUVr) as primary outcome measures. Visual ratings of PET image quality and tracer retention or β-amyloid (Aβ) binding expressed as SUVrs were compared after intravenous administration of either 111 MBq (3 mCi) or 370 MBq (10 mCi) of florbetapir F 18 in patients with Alzheimer's disease (AD) (n = 9) and younger healthy controls (YHCs) (n = 11). In a separate set of subjects (AD, n = 10; YHCs, n = 10), test-retest reliability was evaluated by comparing intrasubject visual read ratings and SUVrs for 2 PET images acquired within 4 wk of each other. RESULTS: There were no meaningful differences between the 111-MBq (3-mCi) and 370-MBq (10-mCi) dose in the visual rating or SUVr. The difference in the visual quality across 111 and 370 MBq showed a trend toward lower image quality, but no statistical significance was achieved (t test; t(1) = -1.617, P = 0.12) in this relatively small sample of subjects. At both dose levels, visual ratings of amyloid burden identified 100% of AD subjects as Aβ-positive and 100% of YHCs as Aβ-negative. Mean intrasubject test-retest variability for cortical average SUVrs with the cerebellum as a reference over the 50- to 70-min period was 2.4% ± 1.41% for AD subjects and 1.5% ± 0.84% for controls. The overall SUVr test-retest correlation coefficient was 0.99. The overall κ-statistic for test-retest agreement for Aβ classification of the masked reads was 0.89 (95% confidence interval, 0.69-1.0). CONCLUSION: Florbetapir F 18 appears to have a wide effective dose range and a high test-retest reliability for both quantitative (SUVr) values and visual assessment of the ligand. These imaging performance properties provide important technical information on the use of florbetapir F 18 and PET to detect cerebral amyloid aggregates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Measurement of Observer Agreement for Categorical Data
Landis, J. R., & Koch, G. G. (1977) · Biometrics · doi:10.2307/2529310 · Cited by 81,148
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Statistical Methods for Rates and Proportions
Fleiss, J. L., Levin, B., & Paik, M. C. (2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471445428 · Cited by 18,646
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Statistical Parametric Mapping: The Analysis of Functional Brain Images
Penny, W. D., Friston, K. J., Ashburner, J., Kiebel, S. J., & Thomas, N. (2007) · UCL Discovery (University College London) · Cited by 3,656
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
The Clinical Diagnosis of Alzheimer's Disease
Wade, J. P. H., Mirsen, T. R., Hachinski, V. C., Fisman, M., Lau, C., & Merskey, H. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520130016010 · Cited by 1,374
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117
Self-citation[ 11 C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease
Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · cited 1×
“The unweighted average cortical SUVr was calculated by combining the individual values for each of the cortical regions (22,23).”
MethodSelf-citationAPOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging
Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830
Self-citationEvolution of the neuropathology of Alzheimer's disease
Braak, H., & Braak, E. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05866.x · Cited by 710 · cited 1×
“As amyloid deposition has been described in cognitively normal subjects over 55 y of age (19,20), control subjects in this study had to be between the ages of 35 and 55 y (inclusive) and free of cognitive impairment by history and examination.”
BackgroundWong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684 · cited 1×
“Florbetapir F 18 (18F-AV-45) is an 18F amyloid PET ligand with rapid brain uptake and rapid washout from gray tissues not containing amyloid, high affinity to aggregated b-amyloid, a short imaging time, good separation between the amyloid retention and background signal, and a long, stable pseudoequilibrium permitting…”
BackgroundSelf-citationRowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671
Self-citation18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial
Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., Hasselbalch, S., Law, I., Andersen, A., Korner, A., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22068 · Cited by 646
Barthel, H., Gertz, H.-J., Dresel, S., Peters, O., Bartenstein, P., Buerger, K., Hiemeyer, F., Wittemer-Rump, S. M., Seibyl, J., Reininger, C., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70077-1 · Cited by 591
Self-citationLopresti, B. J., Klunk, W. E., Mathis, C. A., Hoge, J. A., Ziolko, S. K., Lu, X., MELTZER, C. C., Schimmel, K., Tsopelas, N. D., DeKosky, S. T., et al. (2005) · PubMed · Cited by 543
Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions
Bennett, D. A., Schneider, J. A., Bienias, J. L., Evans, D. A., & Wilson, R. S. (2005) · Neurology · doi:10.1212/01.wnl.0000152982.47274.9e · Cited by 537
Klunk, W. E., Wang, Y., Huang, G.-F., Debnath, M. L., Holt, D. P., & Mathis, C. A. (2001) · Life Sciences · doi:10.1016/s0024-3205(01)01232-2 · Cited by 457
Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case Series
Lim, A., Tsuang, D., Kukull, W., Nochlin, D., Leverenz, J., McCormick, W., Bowen, J., Teri, L., Thompson, J., Peskind, E. R., et al. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb02571.x · Cited by 451
Morris, J. C., Edland, S., Clark, C., Galasko, D., Koss, E., Mohs, R., van Belle, G., Fillenbaum, G., & Heyman, A. (1993) · Neurology · doi:10.1212/wnl.43.12.2457 · Cited by 441
Self-citationFleisher, A. S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.150 · Cited by 364
Nelissen, N., Van Laere, K., Thurfjell, L., Owenius, R., Vandenbulcke, M., Koole, M., Bormans, G., Brooks, D. J., & Vandenberghe, R. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.063305 · Cited by 330
Koole, M., Lewis, D. M., Buckley, C., Nelissen, N., Vandenbulcke, M., Brooks, D. J., Vandenberghe, R., & Van Laere, K. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060756 · Cited by 212
Multicenter clinicopathological correlation in dementia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.10.1476 · Cited by 186
Biomarkers for Early Detection of Alzheimer Pathology
Clark, C. M., Davatzikos, C. A., Borthakur, A., Newberg, A. B., Leight, S., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Neurosignals · doi:10.1159/000109754 · Cited by 105
Self-citationWeighted Least-Squares Approach for Comparing Correlated Kappa
Barnhart, H. X., & Williamson, J. M. (2002) · Biometrics · doi:10.1111/j.0006-341x.2002.01012.x · Cited by 80
Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease
Tolboom, N., Yaqub, M. M., Boellaard, R., Luurtsema, G., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1129-6 · Cited by 77
Diagnosis of Alzheimer's Disease in a Community Hospital-Based Brain Bank Program
Pearl, G. (1997) · Southern medical journal (Birmingham, Ala. Print) · doi:10.1097/00007611-199707000-00013 · Cited by 28
Cited by
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Self-citationAmyloid deposition, hypometabolism, and longitudinal cognitive decline
Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., Weiner, M. W., Jagust, W. J., & Initiative, F. T. A. D. N. (2012) · Annals of Neurology · doi:10.1002/ana.23650 · Cited by 727
Self-citationAssociation Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition
Gottesman, R. F., Schneider, A. L. C., Zhou, Y., Coresh, J., Green, E., Gupta, N., Knopman, D. S., Mintz, A., Rahmim, A., Sharrett, A. R., et al. (2017) · JAMA · doi:10.1001/jama.2017.3090 · Cited by 650
Cascading network failure across the Alzheimer’s disease spectrum
Jones, D. T., Knopman, D. S., Gunter, J. L., Graff-Radford, J., Vemuri, P., Boeve, B. F., Petersen, R. C., Weiner, M. W., & Jack, C. R. (2016) · Brain · doi:10.1093/brain/awv338 · Cited by 540
Metadata
- Authors
- Joshi, A. D., Pontecorvo, M. J., Clark, C. M., Carpenter, A. P., Jennings, D. L., Sadowsky, C. H., Adler, L. P., Kovnat, K. D., Seibyl, J. P., Arora, A., Saha, K., Burns, J. D., Lowrey, M. J., Mintun, M. A., Skovronsky, D. M., & the Florbetapir F 18 Study Investigators
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2012-02-13
- Volume
- 53
- Issue
- 3
- Pages
- 378-384
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2166536611
- Cited by
- 391
- References
- 31
- FWCI
- 14.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.